The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes of SINTART 1 and SINTART 2: Two phase II trials of multimodal treatments in patients with locally advanced sinonasal carcinomas.
 
Arianna Ottini
No Relationships to Disclose
 
Stefano Cavalieri
Expert Testimony - ACCMED
 
Carlo Resteghini
Consulting or Advisory Role - Regeneron
 
Paolo Castelnuovo
No Relationships to Disclose
 
Piero Nicolai
No Relationships to Disclose
 
Ester Orlandi
No Relationships to Disclose
 
Paolo Bossi
Honoraria - BeiGene; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; LEO Pharma; Merck; Merus; MSD Oncology; Nutricia; Pfizer; Regeneron; Sun Pharma
Consulting or Advisory Role - Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck Serono; MSD Oncology; Nutricia; Sanofi/Regeneron; Sun Pharma
Research Funding - AstraZeneca (Inst); BeiGene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Merus NV (Inst); MSD Oncology (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Barbara Vischioni
No Relationships to Disclose
 
Alberto Schreiber
No Relationships to Disclose
 
Nicola Alessandro Iacovelli
No Relationships to Disclose
 
Paolo Battaglia
No Relationships to Disclose
 
Mario Turri-Zanoni
No Relationships to Disclose
 
Davide Mattavelli
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Marco Ravanelli
No Relationships to Disclose
 
Carla Facco
No Relationships to Disclose
 
Tiziana Tartaro
No Relationships to Disclose
 
Laura Locati
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Johnson & Johnson; MSD
 
Marco Ferrari
No Relationships to Disclose
 
Lisa Licitra
Honoraria - ALTIS Omnia Pharma Service Srl; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; Alentis Therapeutics; AVEO; BeOne Medicines Italy S.r.l.; Bicara Therapeutics; Genmab; GlaxoSmithKline; GlaxoSmithKline AG Zweigniederlassung Baar/Zug; Janssen; Janssen Cilag S.p.A.; Janssen Cilag S.p.A.; Janssen Research & Development; Leo Pharma A/S; MedImmune; Merck Healtcare KGaA; Merck Serono; MSD; Pfizer; Purple Biotech; Purple Biotech, Ltd; Regeneron; Roche; Simon-Kucher and Partners Italia S.r.l.; Takeda Pharmaceuticals USA, Inc; Urogen pharma
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); Ascendis Pharma Oncology Division A/S (Inst); AstraZeneca (Inst); AVEO Pharmaceuticals, Inc (Inst); BeiGene (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); Incyte (Inst); InhibRx Biosciences (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Merck Sharp&Dome Corp (Inst); Merus NV (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sciences, Inc (Inst); Sun Pharmaceutica (Inst); Syneos Health (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences